Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C
- 6 July 2023
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (9) , 746-755
Abstract
Chronic hepatitis C (HCV) is a primary cause of hepatocellular carcinoma (HCC). Although antiviral treatment reduces risk of HCC, few studies quantify the impact of treatment on long‐term risk in the era of direct‐acting antivirals (DAA). Using data from the Chronic Hepatitis Cohort Study, we evaluated the impact of treatment type (DAA, interferon‐based [IFN], or none) and outcome (sustained virological response [SVR] or treatment failure [TF]) on risk of HCC. We then developed and validated a predictive risk model. 17186 HCV patients were followed until HCC, death or last follow‐up. We used extended landmark modelling, with time‐varying covariates and propensity score justification and generalized estimating equations with a link function for discrete time‐to‐event data. Death was considered a competing risk. We observed 586 HCC cases across 104,000 interval‐years of follow‐up. SVR from DAA or IFN‐based treatment reduced risk of HCC (aHR 0.13, 95% CI 0.08–0.20; and aHR 0.45, 95% CI 0.31–0.65); DAA SVR reduced risk more than IFN SVR (aHR 0.29, 95% CI 0.17–0.48). Independent of treatment, cirrhosis was the strongest risk factor for HCC (aHR 3.94, 95% CI 3.17–4.89 vs. no cirrhosis). Other risk factors included male sex, White race and genotype 3. Our six‐variable predictive model had ‘excellent’ accuracy (AUROC 0.94) in independent validation. Our novel landmark interval‐based model identified HCC risk factors across antiviral treatment status and interactions with cirrhosis. This model demonstrated excellent predictive accuracy in a large, racially diverse cohort of patients and could be adapted for ‘real world’ HCC monitoring.Keywords
Funding Information
- AbbVie
- Centers for Disease Control and Prevention
- Gilead Sciences
- GlaxoSmithKline
This publication has 20 references indexed in Scilit:
- GES: A validated simple score to predict the risk of HCC in patients with HCV‐GT4‐associated advanced liver fibrosis after oral antiviralsLiver International, 2020
- Incorporating longitudinal biomarkers for dynamic risk prediction in the era of big data: A pseudo‐observation approachStatistics in Medicine, 2020
- The association between etiology of hepatocellular carcinoma and race‐ethnicity in FloridaLiver International, 2020
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus InfectionAnnals of Internal Medicine, 2017
- Time-dependent ROC curve analysis in medical research: current methods and applicationsBMC Medical Research Methodology, 2017
- Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort studyBMJ Open Gastroenterology, 2016
- Modeling Discrete Time-to-Event Data2016
- Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected VeteransAmerican Journal of Gastroenterology, 2014
- HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCVHepatology, 2014
- Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic responseHepatology, 2002